Результаты поиска

Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma.

We investigated the impact of renal impairment (RI) on the outcome in multiple myeloma (MM) patients following induction and autologous stem cell transplantation (ASCT). Among 349 patients who received a first ASCT for MM, 86 (24.6%) had RI at diagnosis, defined as estimation of glomerular filtration rate (eGFR) 2 according to the modification of diet in renal disease (MDRD) formula. Post induction reversal of renal function occurred in 68 (79%) patients including complete renal response in 37.2%. Two hundred and fifty-one patients had received novel agents for induction; posttransplant comple

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.

BackgroundThe China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies.MethodsPatients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1-21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in 28-day cycles. Randomization was stratified according to number of prior therapies, disease stage,

Результаты для неизбранных, недавно диагностированных пациентов с миеломой.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Secondary Hemophagocytic Syndrome in a Patient with Plasma Cell Myeloma and CNS Involvement Treated with Lenalidomide.

We present an extremely rare case report of a 29-year-old multiple myeloma patient with central nervous system involvement and secondary hemophagocytic lymphohistiocytosis (HLH). We observed that HLH was presumably triggered by the immunomodulatory drug-lenalidomide. HLH is frequently misdiagnosed or underdiagnosed. As HLH requires immediate treatment, our report emphasizes the need to consider HLH in the differential diagnosis when the condition of a patient receiving chemotherapy rapidly deteriorates and an infectious etiology is excluded. We furthermore discuss the pathogenesis of HLH, with

Celiac Disease Emerging After ASCT in Multiple Myeloma: A Rare Diagnostic Intersection and Literature Review.

BackgroundAutologous stem cell transplantation (ASCT) is a standard component of therapy for eligible patients with multiple myeloma. Persistent gastrointestinal symptoms after ASCT are commonly attributed to infection, medication-related toxicity, or disease relapse, whereas autoimmune enteropathies such as celiac disease are rarely considered.Case presentationWe report a 53-year-old woman with lambda light-chain multiple myeloma who achieved complete remission after bortezomib, lenalidomide, and dexamethasone induction followed by ASCT and lenalidomide maintenance. Four months after transpla

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Perspective recommendations on geriatric support for older adults with multiple myeloma based on challenges faced by a multidisciplinary team.

BACKGROUND: Multiple Myeloma (MM) predominantly affects older adults, with a median diagnosis age of 70 years, posing challenges in management due to frailty, comorbidities, and age-related physiological changes. As the aging population grows, the prevalence of MM in older patients is expected to rise, requiring improved clinical strategies. METHODS: This consensus report outlines a multidisciplinary framework for the identification, geriatric assessment (GA), and management of older adults with MM, emphasizing the role of frailty assessments, such as the IMWG frailty score, in tailoring trea

Belantamab mafodotin, bortezomib и dexamethasone для RRM в японской группе расширения фазы 3 DREAMM-7 суд.

Случайный, фазы 3 DREAMM-7 судебное разбирательствоNCT04246047) ранее продемонстрировали эффективность и безопасность белантамбового мафодотина, борцезомиба и дексаметазона (BVd) в сравнении с даратумумумабом, бортезомибом и дексаметазоном (DVd) у пациентов с повторной/реактивной множественной миеломой (RRMMM) и ≥ 1 предыдущая терапия. Результаты расширения Японии DREAMM-7, состоящая из 24 - пациенты, случайные для получения BVd (N = 10) или DVd (N = 14), представлены здесь. Средний показатель последующей деятельности 19.4 месяцев (дальность, 1.3-30.3). b) не было достигнуто выживаемости в усл

Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients.

INTRODUCTION: High-risk multiple myeloma (HRMM) is primarily defined by adverse cytogenetic abnormalities that are associated with inferior outcomes despite contemporary treatment with novel induction agents and autologous stem cell transplantation (ASCT). While the accumulation of high-risk lesions has been proposed to further stratify prognosis, the relative impact of single-hit versus double-hit HRMM on post-transplant outcomes in real-world clinical practice remains incompletely characterized. METHODS: We conducted a multicenter retrospective cohort study of transplant-eligible adults wit

The role of carfilzomib in relapsed/refractory multiple myeloma.

Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provi

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.

Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The safety and efficacy of pomalidomide, low-dose dexamethasone, and daratumumab was evaluated in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM) after one to two prior treatment lines in the phase 2 MM-014 study. Patients received pomalidomide 4 mg daily from days 1-21 and dexamethasone 40 mg weekly (28-day cycles). Daratumumab 16 mg/kg was administered per label. Pr

Molecularly targeted therapy and immunotherapy in leukemias.

The advent of next-generation high-throughput sequencing and precision medicine has allowed the identification of recurrent genetic events of vital interest for leukemic cells and for the management of patients with leukemia, since it has a direct impact on prognosis and therapeutic stratification. The precise cytogenetic characterization of these diseases has rapidly enabled the development of innovative therapeutic strategies to improve outcomes and limit toxicities. New targeted therapies, including small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug

Influence of Hypoxia on Tumor Heterogeneity, DNA Repair, and Cancer Therapy: From Molecular Insights to Therapeutic Strategies.

Hypoxia, characterized by a reduction in tissue oxygen levels, is a hallmark of many solid tumors and affects a range of cellular processes, including DNA repair. In low-oxygen conditions, cancer cells often suppress key DNA repair pathways such as homologous recombination (HR), leading to the accumulation of DNA damage and increased genomic instability. These changes not only drive tumor progression but also contribute to resistance against conventional therapies. Hypoxia significantly reduces the effectiveness of oxygen-dependent treatments, including radiotherapy and many chemotherapeutic a

Shoulder Pain in a 33-Year-Old Male Found to Have Multiple Myeloma.

Multiple myeloma (MM) is a blood cancer involving monoclonal plasma cells, mainly diagnosed in older adults. Only a very small percentage of patients are diagnosed before age 40. A 33-year-old male presented with hip and shoulder pain and was diagnosed with Immunoglobulin G (IgG) kappa multiple myeloma. Of the CRAB (calcium elevation, renal insufficiency, anemia, and bone lesions) criteria, he only exhibited anemia and bone lesions. He was found to have extensive osseous lesions throughout his skeleton and a bone marrow biopsy showing plasma cell myeloma involving 30% of medullary cellularity.

Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ixazomib-Thaldomide-Dexametason Вводный курс, проводимый Ixazomib или Placeb в условиях нетрансплантации HOVON-126/НМГС 21.13.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma.

Edward Libby, MD, and Josh Epworth, ARNP, interpreted data on current and novel treatments, discussed how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluated the use of minimal residual disease testing in patients with multiple myeloma.

Совпадение в полном тексте источника
… For initial treatment, triplets are now the standard of care, but regimens containing four drugs are being considered for upfront treatment. Lenalidomide/bortezomib/dexamethasone (RVd) on a 21-day cycle is the gold standard backbone. …

Немногодействующий клеточный ассоциированный гематотоксичный с вторичным миэлофиброзом после Идекабтаген-Виклеукеля для множественной миеломы, полностью обработанный аутентичным гематопоэтическим сетком.

Panktopenia в сочетании с химериковой антигенной рецепторной клеткой T (CAR-T) называется иммунной гематопоиетической токсичностью (ICAHT), которая часто устойчива и противодействует поддержке. Мы сообщаем о случае 52-year-old Человек с множественной миеломой, который развил серьёзный ИКАХТ с вторичным миэлофиброзом (SMF) после введения идекабатагена-виклеукаля, который был полностью усовершенствован за счет аутологического гематопоиетического усиления стволовых клеток. В данном случае основное внимание уделяется СМФ как редким, но осторожным осложнениям CAR-T-терапии, что подчеркивает важност

Non-secretory Multiple Myeloma: A Report of a Rare Case.

Multiple myeloma (MM) is a rare blood cancer. Non-measurable MM (NMMM) is a category designation consisting of both non-secretory MM (NSMM) and oligo-secretory MM (OSMM), both of which have negative findings on serum protein electrophoresis and urine protein electrophoresis testing. NSMM and OSMM are infrequent subtypes. This report describes the case of a 67-year-old female patient without significant past medical history who presented with back pain, nausea, fatigue, and mild confusion. Labs were significant for severe hypercalcemia. Imaging demonstrated osteopenia and multiple lytic lesions

Double-Hit Primary Plasma Cell Leukemia with IGH/MYC and IGH/CCND1 Translocations.

Primary plasma cell leukemia (pPCL) is an aggressive variant of multiple myeloma (MM). Immunoglobulin heavy chain (IgH) translocations are found in a majority of pPCL cases, supporting a central relation to pathogenesis of pPCL. However, two independent IgH translocations are barely detected at the onset of pPCL, and their significance is yet to be elucidated. Here, we report a case of an aggressive pPCL with simultaneous IGH/MYC and IGH/CCND1 translocations. A 73-year-old man was referred to our hospital with back pain and diagnosed as having pPCL with more than 50% circulating plasma cells.